Obinutuzumab in a patient with chronic lymphocytic leukemia-associated paraneoplastic pemphigus

Johanna Freund; Franz Trautinger; Gerhard Kopetzky; Knut Prillinger

doi:10.1016/j.jdcr.2022.07.011

Obinutuzumab in a patient with chronic lymphocytic leukemia-associated paraneoplastic pemphigus

JAAD Case Rep. 2022 Jul 16:27:114-116. doi: 10.1016/j.jdcr.2022.07.011. eCollection 2022 Sep.

Authors

Johanna Freund¹, Franz Trautinger^{1

2}, Gerhard Kopetzky³, Knut Prillinger^{1

2}

Affiliations

¹ Department of Dermatology and Venereology, University Hospital of St Pölten, St Pölten, Austria.
² Karl Landsteiner Institute of Dermatological Research, St Pölten, Austria.
³ Department of Internal Medicine-Clinical Department of Internal Medicine I, University Hospital of St Pölten, Karl Landsteiner University of Health Sciences, St Pölten, Austria.

No abstract available

Keywords: CLL, chronic lymphocytic leukemia; DIF, direct immunofluorescence; Dsg, desmoglein; IVIG, intravenous immunoglobulin; PNP, paraneoplastic pemphigus; autoimmune bullous dermatosis; chronic lymphocytic leukemia; immunosuppression; obinutuzumab; paraneoplastic syndrome.

Publication types

Case Reports